Skip to main content
Premium Trial:

Request an Annual Quote

Jason Gammack

Gene editing technology company Inscripta has appointed Jason Gammack as its first chief commercial officer. Gammack will design and oversee Inscripta's sales, marketing, business development, and customer support operations. He most recently served as vice president of Qiagen's life science business, where he led the development of the life science portfolio and go-to-market strategy. Prior to Qiagen, Gammack developed commercialization growth strategies at bioinformatics company Ingenuity Systems, which was acquired by Qiagen in 2013, and has also held senior leadership roles at Sigma-Aldrich, Life Technologies, Affymetrix, and Promega.  

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.